Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota

Barbara Lomeli, Nebojša Janjić, Wael Elamin et al.|Antimicrobial Agents and Chemotherapy|2019

Cited by 38